4 SC AG News - VSC

FeaturedNorth Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC AG (FWB:VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today...

4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune...

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune and...

4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-B Pathways

4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications...

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC AG (Frankfurt, Prime Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced the grant of an exclusive...

4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202

4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company, today announced that the first patient has been...

4SC Announces Financial Results 2010

4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications...

4SC Presents Final Phase IIa Data on Vidofludimus in Inflammatory Bowel Disease Study at the 6th ECCO IBD Conference

4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications...

4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium

4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, will...

4SC Announces First Patient Dosed in Phase I/II SHORE Study in KRAS-Mutant Colorectal Cancer Patients with Resminostat

4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company, today announced that the first patient has...

4SC Completes Enrolment of the Phase IIb COMPONENT Trial with Vidofludimus in Rheumatoid Arthritis

4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

4 SC AG (VSC)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

VSC News

FeaturedNorth Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model

4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-B Pathways

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202

4SC Announces Financial Results 2010

4SC Presents Final Phase IIa Data on Vidofludimus in Inflammatory Bowel Disease Study at the 6th ECCO IBD Conference

4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium

4SC Announces First Patient Dosed in Phase I/II SHORE Study in KRAS-Mutant Colorectal Cancer Patients with Resminostat

4SC Completes Enrolment of the Phase IIb COMPONENT Trial with Vidofludimus in Rheumatoid Arthritis

VSC Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

4 SC AG (VSC) News

4 SC AG (VSC)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

VSC News

FeaturedNorth Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton

4SC's Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat ...

4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma

European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC's Resminostat to Treat Hep...

FDA Grants Orphan Drug Designation to 4SC's Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma

4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis

EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model

4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-B Pathways

4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202

4SC Announces Financial Results 2010

4SC Presents Final Phase IIa Data on Vidofludimus in Inflammatory Bowel Disease Study at the 6th ECCO IBD Conference

4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium

4SC Announces First Patient Dosed in Phase I/II SHORE Study in KRAS-Mutant Colorectal Cancer Patients with Resminostat

4SC Completes Enrolment of the Phase IIb COMPONENT Trial with Vidofludimus in Rheumatoid Arthritis

VSC Discussion

Your Recent History